HER3-DXd Withdraws Market Application: What Lies Ahead for ADC Innovative Drugs?
This article has a total of2229words, reading time:3-4 minutes ｜Author: MaxTom On May 29, 2025, Merck and Daiichi Sankyo jointly announced thevoluntary withdrawal of the market application for the HER3-targeted antibody-drug conjugate (ADC), Patritumab deruxtecan (HER3-DXd), which was originally seeking accelerated approval for the treatment of patients with advanced non-small cell lung cancer (NSCLC) who … Read more